https://doi.org/10.4081/cc.2025.15781
Alexithymia profile across migraine subtypes: a cross-sectional study
Submitted: 22 February 2025
Accepted: 17 July 2025
Published: 25 August 2025
Accepted: 17 July 2025
Abstract Views: 4
PDF: 1
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Background: Migraine is a prevalent neurological disorder, with chronic migraine (CM) and medication overuse headache (MOH) often comorbid with psychiatric conditions. Patients with CM may experience social cognitive impairments, including alexithymia, which could contribute to their condition’s severity and prognosis. This study aims to characterize alexithymia in patients with episodic migraine (EM) and CM and explore differences in alexithymia between patients with and without aura.
Methods: This cross-sectional study included adult patients with EM, CM (with or without MOH), and healthy controls (HCs), conducted at two tertiary headache centers in Italy. Participants completed the Toronto Alexithymia Scale-20 (TAS-20) to assess alexithymia levels. Demographic, clinical, and cognitive functioning data were collected. Migraine features, including frequency, aura symptoms, and medication usage, were also recorded.
Results: The cohort included 200 migraine individuals and 79 HCs. Patients with CM exhibited significantly higher alexithymia scores (56.0±13.2) compared to EM patients (47.8±12.0, p<0.001) and HCs (44.5±11.9, p<0.001). A higher proportion of CM patients (32.0%) had pathological alexithymia compared to EM patients (16.0%) and HCs (9.0%) (overall difference, p<0.001). No significant differences were found in TAS-20 scores between migraine individuals with aura (45.2±9.9) and those without aura (49.5±13.0, p=0.182).
Conclusions: Patients with CM exhibit higher levels of alexithymia compared to those with EM and HCs. These findings suggest that alexithymia may be a more specific trait of CM. Future research should investigate the role of alexithymia in migraine management, particularly in relation to its impact on quality of life and treatment outcomes.
1. Jette N, Patten S, Williams J, Becker W, Wiebe S. Comorbidity of migraine and psychiatric disorders--a national population-based study. Headache 2008;48:501-16.
DOI: https://doi.org/10.1111/j.1526-4610.2007.00993.x
2. Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A, et al. Migraine: epidemiology and systems of care. Lancet 2021;397:1485-95.
DOI: https://doi.org/10.1016/S0140-6736(20)32160-7
3. Cupini LM, Sarchielli P, Calabresi P. Medication overuse headache: neurobiological, behavioural and therapeutic aspects. Pain 2010;150:222-4.
DOI: https://doi.org/10.1016/j.pain.2010.05.003
4. Cupini LM, De Murtas M, Costa C, Mancini M, Eusebi P, Sarchielli P, et al. Obsessive-compulsive disorder and migraine with medication-overuse headache. Headache 2009;49:1005-13.
DOI: https://doi.org/10.1111/j.1526-4610.2009.01457.x
5. Premack D, Woodruff G. Does the chimpanzee have a theory of mind? Behav Brain Sci 1978;1:515-26.
DOI: https://doi.org/10.1017/S0140525X00076512
6. Romozzi M, Di Tella S, Rollo E, Quintieri P, Silveri MC, Vollono C, Calabresi P. Theory of Mind in migraine and medication-overuse headache: A cross-sectional study. Front Neurol 2022;13:968111.
DOI: https://doi.org/10.3389/fneur.2022.968111
7. Pisani S, Murphy J, Conway J, Millgate E, Catmur C, Bird G. The relationship between alexithymia and theory of mind: A systematic review. Neurosci Biobehav Rev 2021;131:497-524.
DOI: https://doi.org/10.1016/j.neubiorev.2021.09.036
8. Di Tella M, Adenzato M, Catmur C, Miti F, Castelli L, Ardito RB. The role of alexithymia in social cognition: Evidence from a non-clinical population. J Affect Disord 2020;273:482-92.
DOI: https://doi.org/10.1016/j.jad.2020.05.012
9. Natalucci G, Faedda N, Quinzi A, Alunni Fegatelli D, Vestri A, Turturo G, et al. Alexithymia, Metacognition, and Theory of Mind in Children and Preadolescents With Migraine Without Aura (MWoA): A Case-Control Study. Front Neurol 2019;10:774.
DOI: https://doi.org/10.3389/fneur.2019.00774
10. Galli F, Caputi M, Sances G, Vegni E, Bottiroli S, Nappi G, et al. Alexithymia in chronic and episodic migraine: a comparative study. J Ment Health 2017;26:192-6.
DOI: https://doi.org/10.3109/09638237.2015.1124404
11. Bottiroli S, Galli F, Viana M, Sances G, Tassorelli C. Traumatic Experiences, Stressful Events, and Alexithymia in Chronic Migraine With Medication Overuse. Front Psychol 2018;9:704.
DOI: https://doi.org/10.3389/fpsyg.2018.00704
12. Santangelo G, Siciliano M, Pedone R, Vitale C, Falco F, Bisogno R, et al. Normative data for the Montreal Cognitive Assessment in an Italian population sample. Neurol Sci 2015;36:585-91.
DOI: https://doi.org/10.1007/s10072-014-1995-y
13. Silveri MC, Di Tella S, Lo Monaco MR, Petracca M, Tondinelli A, Antonucci G, et al. Theory of mind: A clue for the interpretation of functional movement disorders. Acta Neurol Scand 2022.
DOI: https://doi.org/10.1111/ane.13585
14. Bottiroli S, Rosi A, Sances G, Allena M, De Icco R, Lecce S, et al. Social cognition in chronic migraine with medication overuse: a cross-sectional study on different aspects of mentalization and social relationships. J Headache Pain 2023;24:47.
DOI: https://doi.org/10.1186/s10194-023-01578-1
15. Biscetti L, Cresta E, Cupini LM, Calabresi P, Sarchielli P. The putative role of neuroinflammation in the complex pathophysiology of migraine: From bench to bedside. Neurobiol Dis 2023;180:106072.
DOI: https://doi.org/10.1016/j.nbd.2023.106072
16. Galli F, Pozzi G, Frustaci A, Allena M, Anastasi S, Chirumbolo A, et al. Differences in the personality profile of medication-overuse headache sufferers and drug addict patients: a comparative study using MMPI-2. Headache 2011;51:1212-27.
DOI: https://doi.org/10.1111/j.1526-4610.2011.01978.x
17. Nyklíček I, Vingerhoets A. Alexithymia is associated with low tolerance to experimental painful stimulation. Pain 2000;85:471-5.
DOI: https://doi.org/10.1016/S0304-3959(99)00295-X
18. Kano M, Fukudo S. The alexithymic brain: the neural pathways linking alexithymia to physical disorders. Biopsychosoc Med 2013;7:1.
DOI: https://doi.org/10.1186/1751-0759-7-1
19. Coppola G, Ambrosini A. What has neurophysiology revealed about migraine and chronic migraine? Handb Clin Neurol. 2023;198:117-33.
DOI: https://doi.org/10.1016/B978-0-12-823356-6.00003-2
20. Lane RD, Ahern GL, Schwartz GE, Kaszniak AW. Is alexithymia the emotional equivalent of blindsight? Biol Psychiatry 1997;42:834-44.
DOI: https://doi.org/10.1016/S0006-3223(97)00050-4
21. Maizels M, Aurora S, Heinricher M. Beyond neurovascular: migraine as a dysfunctional neurolimbic pain network. Headache 2012;52:1553-65.
DOI: https://doi.org/10.1111/j.1526-4610.2012.02209.x
22. Vieira RV, Vieira DC, Gomes WB, Gauer G. Alexithymia and its impact on quality of life in a group of Brazilian women with migraine without aura. J Headache Pain 2013;14:18.
DOI: https://doi.org/10.1186/1129-2377-14-18
23. Yalug I, Selekler M, Erdogan A, Kutlu A, Dundar G, Ankarali H, et al. Correlations between alexithymia and pain severity, depression, and anxiety among patients with chronic and episodic migraine. Psychiatry Clin Neurosci 2010;64:231-8.
DOI: https://doi.org/10.1111/j.1440-1819.2010.02093.x
24. Yalınay Dikmen P, Onur Aysevener E, Kosak S, Ilgaz Aydınlar E, Sağduyu Kocaman A. Relationship between MIDAS, depression, anxiety and alexithymia in migraine individuals. Acta Neurol Belg 2020;120:837-44.
DOI: https://doi.org/10.1007/s13760-017-0856-x
25. Pearl TA, Dumkrieger G, Chong CD, Dodick DW, Schwedt TJ. Impact of Depression and Anxiety Symptoms on Patient-Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR). Headache 2020;60:1910-9.
DOI: https://doi.org/10.1111/head.13911
26. Radat F, Swendsen J. Psychiatric comorbidity in migraine: a review. Cephalalgia 2005;25:165-78.
DOI: https://doi.org/10.1111/j.1468-2982.2004.00839.x
27. Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E, et al. Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache 2021;61:662-72.
DOI: https://doi.org/10.1111/head.14097
28. Smitherman TA, Tietjen GE, Schuh K, Skljarevski V, Lipsius S, D'Souza DN, et al. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies. Headache 2020;60:2202-19.
DOI: https://doi.org/10.1111/head.13970
29. Torres-Ferrus M, Gallardo VJ, Alpuente A, Caronna E, Giné-Ciprés E, Pozo-Rosich P. Patterns of response to anti-calcitonin gene-related peptide monoclonal antibodies during first 6 months of treatment in resistant migraine individuals: Impact on outcome. Eur J Neurol 2023;30:1937-44.
DOI: https://doi.org/10.1111/ene.15816
30. Bottiroli S, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M, et al. Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain 2021;22:114.
DOI: https://doi.org/10.1186/s10194-021-01333-4
31. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.
DOI: https://doi.org/10.1177/0333102417738202
32. Conti S, Bonazzi S, Laiacona M, Masina M, Coralli MV. Montreal Cognitive Assessment (MoCA)-Italian version: regression based norms and equivalent scores. Neurol Sci 2015;36:209-14.
DOI: https://doi.org/10.1007/s10072-014-1921-3
33. Bressi C, Taylor G, Parker J, Bressi S, Brambilla V, Aguglia E, et al. Cross validation of the factor structure of the 20-item Toronto Alexithymia Scale: an Italian multicenter study. J Psychosom Res 1996;41:551-9.
DOI: https://doi.org/10.1016/S0022-3999(96)00228-0
How to Cite
1.
Romozzi M, Di Tella S, Vollono C, Abagnale C, Sebastianelli G, Ricotta G, et al. Alexithymia profile across migraine subtypes: a cross-sectional study. Confinia Cephalal [Internet]. 2025 Aug. 25 [cited 2025 Aug. 26];35(1). Available from: https://www.confiniacephalalgica.com/site/article/view/15781
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
